Every 10-Q that Editas Medicine, Inc. (EDIT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EDIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDIT filings page.
Editas Medicine reported second-quarter 2026 collaboration and other research and development revenues of $11.9 million, up from $3.6 million a year earlier, and a net loss of $18.2 million versus $53.2 million. Operating expenses fell sharply, helped by the absence of large prior-year restructuring and impairment charges and by a small restructuring benefit in 2026.
As of June 30 2026, cash, cash equivalents and marketable securities totaled $211.6 million, with net cash used in operating activities of $52.6 million in the first half. A May 2026 underwritten offering of 55.6 million shares and accompanying warrants generated $116.9 million in net proceeds, and a liability for the sale of future revenues stood at $55.7 million. Management expects existing cash and cash equivalents to fund operating expenses and capital needs for at least the next twelve months from August 5 2026.
The company is now centered on its in vivo CRISPR candidate EDIT-401 for heterozygous familial hypercholesterolemia, following discontinuation of the reni‑cel program and a workforce reduction of about 65%. Preclinical data showed around 90% or greater LDL‑C reductions in non‑human primates, and a Phase 1/2 trial in Australia and New Zealand is planned, with initial patient data expected in 2027. Editas also continues to recognize collaboration and license revenues from Bristol‑Myers Squibb and Vertex under existing agreements.
Editas Medicine reported a Q1 2026 net loss of $25.0 million, sharply improved from $76.1 million a year earlier as prior restructuring and impairment charges rolled off and operating costs declined.
Collaboration and other R&D revenue fell to $2.8 million from $4.7 million. Research and development expense dropped to $17.6 million and general and administrative expense to $10.2 million, reflecting the discontinuation of the reni‑cel program and a large workforce reduction completed in 2025.
The company ended March 31, 2026 with $123.6 million in cash and cash equivalents and an accumulated deficit of about $1.7 billion. Management states this cash should fund operations into the third quarter of 2027 while Editas advances lead in vivo gene‑editing candidate EDIT‑401 toward first‑in‑human studies and early proof‑of‑concept data.
Editas Medicine reported Q3 2025 results with collaboration revenue of $7.5 million driven by a BMS milestone. Operating expenses fell sharply after the 2024 program discontinuation, with R&D at $19.8 million and G&A at $12.3 million. The quarter’s operating loss was $24.5 million and net loss was $25.1 million, or $0.28 per share.
Cash and cash equivalents were $165.6 million, and management states existing cash is expected to fund operations into the third quarter of 2027. Year to date, the company recorded $66.9 million of restructuring and impairment charges tied to the wind-down of its ex vivo program, while interest expense reflects its sale of certain future Vertex-related payments. Common shares outstanding were 97,618,660 as of October 31, 2025.
The company raised $25.8 million net through its at-the-market equity program in the first nine months of 2025 and had $123.6 million of capacity remaining as of September 30, 2025. Authorized common stock increased to 390,000,000 shares. Editas is prioritizing in vivo programs, including EDIT-401 for LDL-C reduction.
Editas Medicine (EDIT) reported a net loss of $129.3 million for the six months ended June 30, 2025, or $1.54 per share, widening its accumulated deficit to $1.6 billion. Total assets fell to $210.6 million from $341.6 million at year-end 2024, and stockholders' equity declined to $19.2 million. Cash and cash equivalents were $138.5 million and marketable securities were $39.9 million, totaling $178.5 million in liquid investments.
The company discontinued its ex vivo reni-cel program and initiated a workforce reduction of approximately 180 positions (about 65%), recording $66.9 million of restructuring and impairment charges in the six months and $79.2 million since the December 2024 decision. Editas received $57.0 million from DRI under a sale-of-future-revenues agreement (accounted for as debt; estimated effective interest rate 15.1%, liability $56.7 million) and has an amended ATM facility with $141.4 million remaining capacity after $8.6 million of sales. Management expects existing cash, cash equivalents and marketable securities to fund operations for at least twelve months from the consolidated financial statement issuance date.